Open AccessImpaired protein binding of Chinese medicine DanShen in uremic sera and sera with hyperbilirubinemia: Rapid assessment of total and free Danshen concentrations using the fluorescence polarization immunoassay for digoxin
Author(s) -
Wahed Amer,
Pollard John,
Wells Alice,
Dasgupta Amitava
Publication year - 2003
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.10090
Subject(s) - bilirubin , uremia , binding protein , albumin , medicine , digoxin , chemistry , serum albumin , in vitro , pharmacology , biochemistry , heart failure , gene
DanShen is a Chinese medicine that is used to treat cardiovascular disorders. DanShen is moderately to strongly protein bound, mainly to albumin. Because impaired protein binding of albumin‐bound drugs in uremia has been reported, we studied protein binding of DanShen by measuring the digoxin‐like immunoreactive component of this Chinese medicine. We observed a significantly higher percentage of free fraction of DanShen in uremic sera in vitro. Impaired protein binding of DanShen was also observed in sera from patients with liver disease, who had elevated concentrations of bilirubin. Treating uremic sera with activated charcoal significantly improved the protein binding of DanShen, indicating that uremic compounds are responsible for the impaired protein binding of DanShen. On the other hand, when various amounts of bilirubin were added to aliquots of the normal pool supplemented with DanShen, we observed only a modest displacement of DanShen from the protein‐binding sites by bilirubin, indicating that hypoalbuminemia may play a major role in impaired protein binding of DanShen in sera with elevated bilirubin concentrations. We conclude that protein binding of DanShen is lower in uremic sera and in sera with elevated bilirubin concentrations. J. Clin. Lab. Anal. 17:179–183, 2003. © 2003 Wiley‐Liss, Inc.